Science Corporation, a competitor to Elon Musk’s Neuralink in brain-computer interface (BCI) technology, has announced exciting early results from clinical trials for an eye implant that claims to restore vision for some patients experiencing sight loss. This innovative device, named the PRIMA, is designed to be implanted just beneath the retina. It operates in conjunction with a special pair of glasses and a compact processing unit, enabling patients to regain some visual abilities.

Notably, the PRIMA implant features a unique Zoom capability, allowing users to enlarge specific elements, such as text, for better visibility. This functionality is especially beneficial for individuals suffering from a severe form of age-related macular degeneration known as geographic atrophy (GA).

Macular degeneration primarily affects the macula, the central region of the retina responsible for sharp, detailed vision. It is the leading cause of age-related vision loss, with approximately 80 percent of affected individuals developing the “dry” form of the condition. In this form, the macula thins, leading to the accumulation of protein deposits. Over time, the condition can advance to geographic atrophy, characterized by the loss of retinal cells in certain areas.

Also read: Dubai Reef completes fabricating first 1,000 purpose-built reef modules

The potential impact of the PRIMA device is significant, as it offers hope for those with limited treatment options for advanced macular degeneration. By restoring vision, this technology could greatly enhance the quality of life for patients, allowing them to perform daily activities with greater ease. As Science Corporation progresses with its clinical trials, the medical community eagerly anticipates further developments in this groundbreaking technology.

-Agencies